The Multidrug Transporter ABCG2: Still More Questions Than Answers

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2016 Jun 11

PMID 27284047

Citations 45

Authors

Aaron J Horsey

Megan H Cox

Sunehera Sarwat

Ian D Kerr

Affiliations

Soon will be listed here.

Abstract

ABCG2 is one of at least three human ATP binding cassette (ABC) transporters which can facilitate the export from cells of a wide range of chemically unrelated drug molecules. This capacity for multidrug transport is not only a confounding factor in chemotherapy, but is also one of the more perplexing phenomena in transporter biochemistry. Since its discovery in the last decade of the 20th century much has been revealed about ABCG2's localization, physiological function and its broad substrate range. There have also been many investigations of its structure and molecular mechanism. In this mini review article we take a Rumsfeldian approach to ABCG2 and essentially ask what we do know about this transporter, and what we will need to know about this transporter if we wish to use modulation of ABCG2 activity as a therapeutic approach.

Citing Articles

Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.

Pina-Beltran B, Dimitrov D, McKay N, Giot M, Zdrahal Z, Potesil D Sci Rep. 2025; 15(1):6075.

PMID: 39972038 PMC: 11839926. DOI: 10.1038/s41598-025-90405-5.

The ABCG2 Transporter Affects Plasma Levels, Tissue Distribution and Milk Secretion of Lumichrome, a Natural Derivative of Riboflavin.

Millan-Garcia A, Alvarez-Fernandez L, Blanco-Paniagua E, Alvarez A, Merino G Int J Mol Sci. 2024; 25(18).

PMID: 39337371 PMC: 11431963. DOI: 10.3390/ijms25189884.

Therapy-induced senescence in breast cancer: an overview.

Chembukavu S, Lindsay A Explor Target Antitumor Ther. 2024; 5(4):902-920.

PMID: 39280248 PMC: 11390292. DOI: 10.37349/etat.2024.00254.

Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile.

Morau M, Seguin C, Perroud Junior M, Dagli-Hernandez C, Pincinato E, Moriel P Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204145 PMC: 11359302. DOI: 10.3390/ph17081040.

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment.

Koirala M, DiPaola M Biomedicines. 2024; 12(8).

PMID: 39200265 PMC: 11351918. DOI: 10.3390/biomedicines12081801.

References

Damiani D, Tiribelli M, Geromin A, Michelutti A, Cavallin M, Sperotto A . ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. Am J Hematol. 2015; 90(9):784-9. DOI: 10.1002/ajh.24084. View

Haider A, Briggs D, Self T, Chilvers H, Holliday N, Kerr I . Dimerization of ABCG2 analysed by bimolecular fluorescence complementation. PLoS One. 2011; 6(10):e25818. PMC: 3185054. DOI: 10.1371/journal.pone.0025818. View

Egido E, Muller R, Li-Blatter X, Merino G, Seelig A . Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations. Mol Pharm. 2015; 12(11):4026-37. DOI: 10.1021/acs.molpharmaceut.5b00463. View

Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K . Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004; 10(5):1691-7. DOI: 10.1158/1078-0432.ccr-0937-3. View

Suvannasankha A, Minderman H, OLoughlin K, Nakanishi T, Ford L, Greco W . Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol. 2004; 127(4):392-8. DOI: 10.1111/j.1365-2141.2004.05211.x. View

McDevitt C, Collins R, Kerr I, Callaghan R . Purification and structural analyses of ABCG2. Adv Drug Deliv Rev. 2009; 61(1):57-65. DOI: 10.1016/j.addr.2008.07.004. View

Benderra Z, Faussat A, Sayada L, Perrot J, Chaoui D, Marie J . Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004; 10(23):7896-902. DOI: 10.1158/1078-0432.CCR-04-0795. View

Allikmets R, Schriml L, Hutchinson A, Romano-Spica V, Dean M . A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998; 58(23):5337-9. View

Keskitalo J, Zolk O, Fromm M, Kurkinen K, Neuvonen P, Niemi M . ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009; 86(2):197-203. DOI: 10.1038/clpt.2009.79. View

10.

Mao Q, Unadkat J . Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J. 2014; 17(1):65-82. PMC: 4287283. DOI: 10.1208/s12248-014-9668-6. View

11.

Bai X, McMullan G, Scheres S . How cryo-EM is revolutionizing structural biology. Trends Biochem Sci. 2014; 40(1):49-57. DOI: 10.1016/j.tibs.2014.10.005. View

12.

Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A . The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica. 2006; 91(6):825-8. View

13.

Woodward O, Kottgen A, Coresh J, Boerwinkle E, Guggino W, Kottgen M . Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009; 106(25):10338-42. PMC: 2700910. DOI: 10.1073/pnas.0901249106. View

14.

Rosenberg M, Bikadi Z, Hazai E, Starborg T, Kelley L, Chayen N . Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation. Acta Crystallogr D Biol Crystallogr. 2015; 71(Pt 8):1725-35. PMC: 4528803. DOI: 10.1107/S1399004715010676. View

15.

Henriksen U, Fog J, Litman T, Gether U . Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem. 2005; 280(44):36926-34. DOI: 10.1074/jbc.M502937200. View

16.

Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J . Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol. 2005; 70(5):695-9. DOI: 10.1016/j.bcp.2005.05.031. View

17.

Allen J, van Loevezijn A, Lakhai J, van der Valk M, van Tellingen O, Reid G . Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002; 1(6):417-25. View

18.

Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T . Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol. 2007; 86(2):166-73. DOI: 10.1532/IJH97.E0624. View

19.

Maliepaard M, Scheffer G, Faneyte I, van Gastelen M, Pijnenborg A, Schinkel A . Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001; 61(8):3458-64. View

20.

Kruijtzer C, Beijnen J, Rosing H, Ten Bokkel Huinink W, Schot M, Jewell R . Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol. 2002; 20(13):2943-50. DOI: 10.1200/JCO.2002.12.116. View